Differenzialdiagnosen von Kolitiden

Neben chronisch-entzündlichen Darmerkrankungen sind die mikroskopische Kolitis (kollagene und lymphozytäre Kolitis), die NSAR-induzierte Kolitis und die Checkpoint-Inhibitor-induzierte Kolitis weitere Kolitis-Differenzialdiagnosen, die sich durch eindeutige histologische Befunde bzw. durch definierte ätiologische Auslöser auszeichnen. Wir geben einen Überblick über Pathogenese, diagnostisch wegweisende Kriterien und empfohlene Therapieansätze.

Kernaussagen

Mikroskopische Kolitis

• Das Leitsymptom der mikroskopischen Kolitis ist die wässrige, typischerweise nachts auftretende Diarrhö.

• Pathognomisch für die LC ist eine Infiltration der Mukosa mit > 20 IEL pro 100 Epithelzellen. Die CC ist durch ein > 10 µm messendes subepitheliales Kollagenband definiert.

• Die enterale Anwendung von Budesonid führt meist zu einer raschen klinischen und histologischen Remission. Es besteht allerdings ein erhebliches Rezidivrisiko nach Absetzen der Therapie.

NSAR-induzierte Kolitis/Enteropathie

• Bei ungeklärten Diarrhöen und (zurückliegendem) NSAR-Gebrauch sollte stets eine NSAR-induzierte Kolitis/Enteropathie differenzialdiagnostisch miteinbezogen werden.

• Schwerpunktmäßig ist neben distalen Dünndarm und Kolon die Ileozäkalregion miteinbezogen. Es können neben entzündeter Schleimhaut demarkierte Ulzerationen vorhanden sein.

• Residuelle narbige Stenosen sollten, sofern zugänglich, bevorzugt endoskopisch mittels TTS-Ballondilatation oder Nadelmesser interveniert werden.

CPI-induzierte Kolitis

• CPI-assoziierte Diarrhöen treten durchschnittlich bei 10 von 100 mit PD1- oder PD-L1-Inhibitoren behandelten Patienten auf. Die Prävalenz sowohl von Diarrhöen als auch Kolitis ist im Gefolge einer Therapie mit dem CTLA4-Inhibitor Ipilimumab höher.

• Für die Diagnosestellung sind zeitlicher Zusammenhang zu einer CPI-Therapie, Ausschluss einer infektiösen Genese und endoskopisch-bioptischer Befund entscheidend.

• Bei milden Verläufen (CTCAE Grad 1) ist die Pausierung der CPI-Therapie optional; bei schweren Verläufen (CTCAE Grad 3 und 4) sollte die CPI-Therapie dauerhaft beendet werden.

• Bei moderaten und schweren Verläufen (CTCAE Grad 2 – 4) ist eine systemische Kortikosteroidtherapie unumgänglich. In steroidrefraktären Fällen kann als „Rescue“-Maßnahme eine Biologikatherapie mit Infliximab oder Vedolizumab in Abhängigkeit von Alter, individuellem Infektrisiko und hämatologischen Begleiterkrankungen erfolgen.

Schlüsselwörter

Mikroskopische Kolitis; NSAR-induzierte Enteropathie; Checkpoint-Inhibitor-induzierte Kolitis

Publikationsverlauf

Artikel online veröffentlicht:
21. Juni 2023

• Literatur

• 1 Tong J, Zheng Q, Zhang C. et al. Erratum: Incidence, prevalence, and temporal trends of microscopic colitis: A systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 1121 DOI: 10.1038/ajg.2015.46.
• 2 Davidson S, Sjöberg K, Engel PJH. et al. Microscopic colitis in Denmark and Sweden: incidence, putative risk factors, histological assessment and endoscopic activity. Scand J Gastroenterol 2018; 53: 818-824 DOI: 10.1080/00365521.2018.1476583.
• 3 Verhaegh BP, Jonkers DM, Driessen A. et al. Incidence of microscopic colitis in the Netherlands. A nationwide population-based study from 2000 to 2012. Dig Liver Dis 2015; 47: 30-36 DOI: 10.1016/j.dld.2014.09.019.
• 4 Fumery M, Kohut M, Gower-Rousseau C. et al. Incidence, clinical presentation, and associated factors of microscopic colitis in Northern France: A population-based study. Dig Dis Sci 2017; 62: 1571-1579 DOI: 10.1007/s10620-016-4306-z.
• 5 Westerlind H, Mellander MR, Bresso F. et al. Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis. Gut 2017; 66: 421-428 DOI: 10.1136/gutjnl-2015-309934.
• 6 van Hemert S, Skonieczna-Żydecka K, Loniewski I. et al. Microscopic colitis-microbiome, barrier function and associated diseases. Ann Translat Med 2018; 6: 39 DOI: 10.21037/atm.2017.03.83.
• 7 Kumawat AK, Strid H, Tysk C. et al. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Mol Immunol 2013; 55: 355-364 DOI: 10.1016/j.molimm.2013.03.007.
• 8 Bürgel N, Bojarski C, Mankertz J. et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002; 123: 433-443 DOI: 10.1053/gast.2002.34784.
• 9 Escudero-Hernández C, Münch A, Østvik AE. et al. The water channel aquaporin 8 is a critical regulator of intestinal fluid homeostasis in collagenous colitis. J Crohns Colitis 2020; 14: 962-973 DOI: 10.1093/ecco-jcc/jjaa020.
• 10 Fernandez-Bañares F, Esteve M, Salas A. et al. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig Dis Sci 2001; 46: 2231-2238 DOI: 10.1023/a:1011927302076.
• 11 Günther U, Schuppan D, Bauer M. et al. Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and -13, and TIMP-1 gene expression. Am J Pathol 1999; 155: 493-503 DOI: 10.1016/s0002-9440(10)65145-0.
• 12 Fernández-Bañares F, de Sousa MR, Salas A. et al. Impact of current smoking on the clinical course of microscopic colitis. Inflammatory Bowel Dis 2013; 19: 1470-1476 DOI: 10.1097/MIB.0b013e318281f3cc.
• 13 Burke KE, Ananthakrishnan AN, Lochhead P. et al. Identification of menopausal and reproductive risk factors for microscopic colitis – Results from the Nursesʼ Health Study. Gastroenterology 2018; 155: 1764-1775.e1762 DOI: 10.1053/j.gastro.2018.08.029.
• 14 Bonderup OK, Nielsen GL, Dall M. et al. Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study. Aliment Pharmacol Ther 2018; 48: 618-625 DOI: 10.1111/apt.14916.
• 15 Masclee GM, Coloma PM, Kuipers EJ. et al. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol 2015; 110: 749-759 DOI: 10.1038/ajg.2015.119.
• 16 Verhaegh BP, de Vries F, Masclee AA. et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 2016; 43: 1004-1013 DOI: 10.1111/apt.13583.
• 17 Fernández-Bañares F, de Sousa MR, Salas A. et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflammatory Bowel Dis 2013; 19: 411-417 DOI: 10.1002/ibd.23009.
• 18 Nimri FM, Muhanna A, Almomani Z. et al. The association between microscopic colitis and celiac disease: a systematic review and meta-analysis. Ann Gastroenterol 2022; 35: 281-289 DOI: 10.20524/aog.2022.0714.
• 19 Bjørnbak C, Engel PJ, Nielsen PL. et al. Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups. Aliment Pharmacol Ther 2011; 34: 1225-1234 DOI: 10.1111/j.1365-2036.2011.04865.x.
• 20 Madisch A, Miehlke S, Bartosch F. et al. [Microscopic colitis: clinical presentation, treatment and outcome of 494 patients]. Z Gastroenterol 2014; 52: 1062-1065 DOI: 10.1055/s-0034-1366281.
• 21 Kane JS, Irvine AJ, Derwa Y. et al. Fatigue and its associated factors in microscopic colitis. Therap Adv Gastroenterol 2018; 11: 1756284818799599 DOI: 10.1177/1756284818799599.
• 22 Cotter TG, Binder M, Loftus jr. EV. et al. Development of a microscopic colitis disease activity index: a prospective cohort study. Gut 2018; 67: 441-446 DOI: 10.1136/gutjnl-2016-313051.
• 23 Kane JS, Rotimi O, Everett SM. et al. Development and validation of a scoring system to identify patients with microscopic colitis. Clin Gastroenterol Hepatol 2015; 13: 1125-1131 DOI: 10.1016/j.cgh.2014.12.035.
• 24 Larsson JK, Sonestedt E, Ohlsson B. et al. The association between the intake of specific dietary components and lifestyle factors and microscopic colitis. Eur J Clin Nutr 2016; 70: 1309-1317 DOI: 10.1038/ejcn.2016.130.
• 25 Calabrese C, Fabbri A, Areni A. et al. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J Gastroenterol Hepatol 2007; 22: 809-814 DOI: 10.1111/j.1440-1746.2006.04511.x.
• 26 Fine KD, Lee EL. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology 1998; 114: 29-36 DOI: 10.1016/s0016-5085(98)70629-8.
• 27 Madisch A, Miehlke S, Eichele O. et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis 2007; 22: 1445-1451 DOI: 10.1007/s00384-007-0364-1.
• 28 Baert F, Schmit A, DʼHaens G. et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology 2002; 122: 20-25 DOI: 10.1053/gast.2002.30295.
• 29 Miehlke S, Heymer P, Bethke B. et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002; 123: 978-984 DOI: 10.1053/gast.2002.36042.
• 30 Miehlke S, Aust D, Mihaly E. et al. Efficacy and safety of budesonide, vs. mesalazine or placebo, as induction therapy for lymphocytic colitis. Gastroenterology 2018; 155: 1795-1804.e1793 DOI: 10.1053/j.gastro.2018.08.042.
• 31 Miehlke S, Madisch A, Karimi D. et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology 2009; 136: 2092-2100 DOI: 10.1053/j.gastro.2009.02.078.
• 32 Hjortswang H, Tysk C, Bohr J. et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflammatory Bowel Dis 2009; 15: 1875-1881 DOI: 10.1002/ibd.20977.
• 33 Miehlke S, Guagnozzi D, Zabana Y. et al. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. United Eur Gastroenterol J 2021; 9: 13-37 DOI: 10.1177/2050640620951905.
• 34 Münch A, Mihaly E, Nagy F. et al. Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial. United Eur Gastroenterol J 2021; 9: 837-847 DOI: 10.1002/ueg2.12131.
• 35 Sebastian S, Wilhelm A, Jessica L. et al. Budesonide treatment for microscopic colitis: systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019; 31: 919-927 DOI: 10.1097/meg.0000000000001456.
• 36 Bonderup OK, Hansen JB, Teglbjaerg PS. et al. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut 2009; 58: 68-72 DOI: 10.1136/gut.2008.156513.
• 37 Miehlke S, Madisch A, Bethke B. et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2008; 135: 1510-1516 DOI: 10.1053/j.gastro.2008.07.081.
• 38 Miehlke S, Madisch A, Voss C. et al. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 2005; 22: 1115-1119 DOI: 10.1111/j.1365-2036.2005.02688.x.
• 39 Cotter TG, Kamboj AK, Hicks SB. et al. Immune modulator therapy for microscopic colitis in a case series of 73 patients. Aliment Pharmacol Ther 2017; 46: 169-174 DOI: 10.1111/apt.14133.
• 40 Münch A, Bohr J, Vigren L. et al. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. Clin Exp Gastroenterol 2013; 6: 149-152 DOI: 10.2147/ceg.S48201.
• 41 Riddell J, Hillman L, Chiragakis L. et al. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes. J Gastroenterol Hepatol 2007; 22: 1589-1593 DOI: 10.1111/j.1440-1746.2007.05128.x.
• 42 Esteve M, Mahadevan U, Sainz E. et al. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis 2011; 5: 612-618 DOI: 10.1016/j.crohns.2011.05.001.
• 43 Pola S, Fahmy M, Evans E. et al. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol 2013; 108: 857-858 DOI: 10.1038/ajg.2013.43.
• 44 Rivière P, Münch A, Michetti P. et al. Vedolizumab in refractory microscopic colitis: An international case series. J Crohns Colitis 2019; 13: 337-340 DOI: 10.1093/ecco-jcc/jjy169.
• 45 Järnerot G, Tysk C, Bohr J. et al. Collagenous colitis and fecal stream diversion. Gastroenterology 1995; 109: 449-455 DOI: 10.1016/0016-5085(95)90332-1.
• 46 Bjarnason I, Hayllar J, MacPherson AJ. et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-1847 DOI: 10.1016/0016-5085(93)90667-2.
• 47 Allison MC, Howatson AG, Torrance CJ. et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327: 749-754 DOI: 10.1056/nejm199209103271101.
• 48 Laine L, Curtis SP, Langman M. et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008; 135: 1517-1525 DOI: 10.1053/j.gastro.2008.07.067.
• 49 Goldstein JL, Eisen GM, Lewis B. et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-141 DOI: 10.1016/s1542-3565(04)00619-6.
• 50 Hawkey CJ, Ell C, Simon B. et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008; 6: 536-544 DOI: 10.1016/j.cgh.2007.12.023.
• 51 Bjarnason I, Fehilly B, Smethurst P. et al. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991; 32: 275-277 DOI: 10.1136/gut.32.3.275.
• 52 Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112: 109-117 DOI: 10.1016/s0016-5085(97)70225-7.
• 53 Wallace JL, Syer S, Denou E. et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-1322 1322.e–1322.e5 DOI: 10.1053/j.gastro.2011.06.075.
• 54 Matsuhashi N, Yamada A, Hiraishi M. et al. Multiple strictures of the small intestine after long-term nonsteroidal anti-inflammatory drug therapy. Am J Gastroenterol 1992; 87: 1183-1186
• 55 Ona MA, Patil R, Etienne D. et al. Through-the-scope endoscopic balloon dilatation of a nonsteroidal anti-inflammatory drug-induced diaphragm-like colonic stricture. Ann Gastroenterol 2016; 29: 229 DOI: 10.20524/aog.2016.0020.
• 56 Bundrick C, Ayyagari R, Tharian B. NSAID-induced colitis and colonic stricture: 1597. ACG 2018; 113: S918
• 57 Slesser AA, Wharton R, Smith GV. et al. Systematic review of small bowel diaphragm disease requiring surgery. Colorectal Dis 2012; 14: 804-813 DOI: 10.1111/j.1463-1318.2011.02741.x.
• 58 Nielsen DL, Juhl CB, Chen IM. et al. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treat Rev 2022; 109: 102440 DOI: 10.1016/j.ctrv.2022.102440.
• 59 Garg M, Wahid M, Khan FD. Regulation of peripheral and central immunity: Understanding the role of Src homology 2 domain-containing tyrosine phosphatases, SHP-1 & SHP-2. Immunobiology 2020; 225: 151847 DOI: 10.1016/j.imbio.2019.09.006.
• 60 Li K, Yuan Z, Lyu J. et al. PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. Nat commun 2021; 12: 2746 DOI: 10.1038/s41467-021-22965-9.
• 61 Qin S, Xu L, Yi M. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 2019; 18: 155 DOI: 10.1186/s12943-019-1091-2.
• 62 Dougan M, Luoma AM, Dougan SK. et al. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 2021; 184: 1575-1588 DOI: 10.1016/j.cell.2021.02.011.
• 63 Cohen JV, Dougan M, Zubiri L. et al. Liver biopsy findings in patients on immune checkpoint inhibitors. Modern Pathology 2021; 34: 426-437 DOI: 10.1038/s41379-020-00653-1.
• 64 Marthey L, Mateus C, Mussini C. et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 2016; 10: 395-401 DOI: 10.1093/ecco-jcc/jjv227.
• 65 Luoma AM, Suo S, Williams HL. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 2020; 182: 655-671.e622 DOI: 10.1016/j.cell.2020.06.001.
• 66 Sasson SC, Slevin SM, Cheung VTF. et al. Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology 2021; 161: 1229-1244.e1229 DOI: 10.1053/j.gastro.2021.06.025.
• 67 Messmer M, Upreti S, Tarabishy Y. et al. Ipilimumab-induced enteritis without colitis: A new challenge. Case Rep Oncol 2016; 9: 705-713 DOI: 10.1159/000452403.
• 68 Isidro RA, Ruan AB, Gannarapu S. et al. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis. Histopathology 2021; 78: 532-541 DOI: 10.1111/his.14248.
• 69 Pai RK, Pai RK, Brown I. et al. The significance of histological activity measurements in immune checkpoint inhibitor colitis. Aliment Pharmacol Ther 2021; 53: 150-159 DOI: 10.1111/apt.16142.
• 70 Cheung VTF, Gupta T, Olsson-Brown A. et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. Br J Cancer 2020; 123: 207-215 DOI: 10.1038/s41416-020-0882-y.
• 71 Mooradian MJ, Wang DY, Coromilas A. et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 2020; 8 DOI: 10.1136/jitc-2019-000451.
• 72 Abu-Sbeih H, Ali FS, Luo W. et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018; 6: 95 DOI: 10.1186/s40425-018-0411-1.